CA
Caris Life Sciences, Inc.
CAI · NASDAQ
$29.70 +8.00% (+$2.20)
1M +22.02%
Market Cap $7.77B
P/E Ratio 73.94x
Div. Yield -
ROE 18.77%
Analiza
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Piotroski F-Score Moderate
5/9Valuation
1 /100
Expensive P/E 73.94x
EV/EBITDA 43.63x
P/S 7.86x
Growth
100 /100
Growing Rev. growth 46.46%
EPS growth N/A
FCF growth N/A
Profitability
79 /100
Strong Gross margin 69.66%
Net margin 10.62%
Op. margin 15.49%
Quality
79 /100
Excellent ROIC 14.69%
ROE 18.77%
ROA 8.55%
Debt
78 /100
Low Debt/Equity 0.76x
Current ratio 5.53x
Int. coverage 3.24x
Stability
41 /100
Moderate Beta 0.68x
Rev. volatility 41.46%
EPS volatility 39.17%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o CAI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David Dean Halbert
Employees
1,846
Headquarters
Irving
Prihajajoči dogodki
04 NOV.
Earnings
Upcoming earnings report